13 Best IPO Stocks to Buy According to Wall Street Analysts

Page 10 of 12

3. Neumora Therapeutics Inc. (NASDAQ:NMRA)

Number of Hedge Fund Holders: 18

Average Upside Potential as of August 15: 198.51%

Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study for its drug candidate, called NMRA-861.

The study is being conducted in healthy adult participants and adults with stable schizophrenia. In preclinical studies, NMRA-861 demonstrated a strong pharmacological profile and was found to be safe and well-tolerated.

Neumora expects to report data from the Phase 1 SAD/MAD study in the first quarter of 2026. This data will include assessments of the drug’s safety, tolerability, and human pharmacokinetic data, which will confirm its potential for once-daily dosing and central nervous system penetration.

Neumora Therapeutics Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company that develops therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the US.

Page 10 of 12